New and updated preclinical and clinical data to be presented by biopharma firms at American Society of Clinical Oncology annual meeting, including: Aadi, Adagene, Adaptimmune, Adicet, Advaxis, Amgen, Aura, Biomea.
The American Society of Clinical Oncology (ASCO) updated its guidelines to recommend use of Biotheranostics Inc.’ Breast Cancer Index (BCI) molecular gene-expression test to aid decisions on extended endocrine therapy in certain patients with the most common type of breast cancer.
Modra Pharmaceuticals BV is planning to move its oral formulation of docetaxel into a pivotal trial, hoping to offer advanced prostate cancer patients a safer treatment option than intravenous chemotherapy. The Amsterdam, the Netherlands-based company has just announced phase IIb results in metastatic castration-resistant prostate cancer from ModraDoc-006/r, a tablet containing docetaxel and co-administered with ritonavir to enhance bioavailability.
New and updated preclinical and clinical data presented by biopharma firms at the ASCO Genitourinary
Cancers Symposium, including: Arvinas, Astellas, Astrazeneca, Aura. Aveo, Bioxcel, Janssen, Merck, Mustang, Propella, Seagen.
New and updated preclinical and clinical data presented by biopharma firms at the ASCO Gastrointestinal Cancers Symposium, including: Abivax, Astrazeneca, Cardiff, Chimerix, Exelixis, Immunitybio, ITM, Leap, Merck, Seagen.
New and updated preclinical and clinical data presented by biopharma firms at the ASCO Gastrointestinal Cancers Symposium, including: Abivax, Astrazeneca, Cardiff Oncology, Chimerix, Exelixis, Immunitybio, ITM, Leap, Merck & Co., Seagen.
At the 2021 virtual annual meeting of the American Society for Clinical Oncology (ASCO), results of the VISION trial testing the addition of Novartis AG’s radiopharmaceutical Lutetium-177-PSMA-617 (Lutetium-PSMA) to individualized standard-of-care regimens in metastatic castration-resistant prostate cancer improved both overall survival and radiographic progression-free survival.
At the 2021 virtual annual meeting of the American Society for Clinical Oncology (ASCO), results of the VISION trial testing the addition of Novartis AG’s radiopharmaceutical Lutetium-177-PSMA-617 (Lutetium-PSMA) to individualized standard-of-care regimens in metastatic castration-resistant prostate cancer improved both overall survival and radiographic progression-free survival.
New and updated preclinical and clinical data presented by biopharma firms at the American Society of Clinical Oncology's annual meeting, including: Antengene.
At the 2021 virtual annual meeting of the American Society for Clinical Oncology (ASCO), results of the VISION trial testing the addition of Novartis AG's' radiopharmaceutical lutetium-177-PSMA-617 to individualized standard-of-care regimens in metastatic castration-resistant prostate cancer improved both overall survival and radiographic progression-free survival.
RSS
